There is nothing more critical right now than doing what we can to accelerate potential vaccines, diagnostics, and treatments for COVID-19. We’ve rapidly shifted our entire platform towards COVID-19 response, committing $25M of free access to our infrastructure to projects that can support R&D across a range of applications. I’m thrilled to announce today that […]
Overview Our partner faced significant challenges in scaling up vaccine production to meet global demand due to insufficient yields in both upstream fermentation and downstream processing. Ginkgo Bioworks’s cell engineering platform streamlined our partner’s fermentation and processing, resulting in substantial increases in efficiency and yield. Within ten months, our partner saw improvements that ensured they could meet […]
Overview Our partner encountered a bottleneck in accessing and producing a key enzyme required for scaling-up their vaccines. By leveraging Ginkgo’s cell engineering platform, our partner was able to develop an E. coli expression system for their enzyme expression. Combined with fermentation and processing protocol, we achieved a ten-fold increase in efficiency within a year. […]
Ginkgo epidemiological modeling experts and Northeastern University researchers awarded new grant from the Bill & Melinda Gates Foundation Today we’re thrilled to announce that we’ve been awarded a grant from the Bill & Melinda Gates Foundation to build an open-access, AI-enabled measles forecasting model to empower proactive public health measures, such as immunization campaigns, in […]
Overview Our customer’s commercialization goals required g/L quantities of a protein which was only reported to be produced at the mg/L scale in the literature. Ginkgo’s cell-engineering platform was able to deliver 1,000-fold improvement in titers and provide data-driven guidance during strain engineering to help them achieve commercialization. The challenge A nutrition and wellness […]
Overview The potential commercial value of terpenes Terpenes, which make up one of the largest classes of natural products, have a wide range of applications across industries. Sesqui-, di- and triterpenes, in particular, have found traction as valued ingredients in the pharmaceutical, agricultural, food and nutrition, and fragrance industries. However, these molecules tend to be […]
Today we’re thrilled to announce the creation of the Ginkgo Technology Network — a groundbreaking ecosystem of cutting edge technology partners, each committed to collaborating with Ginkgo to provide new, integrated capabilities to drive success in customer R&D programs. For over 15 years, Ginkgo has invested in building and integrating horizontal platform technologies to […]
Our partner encountered a bottleneck in accessing and producing a key enzyme required for scaling-up their vaccines. By leveraging Ginkgo’s cell engineering platform, our partner was able to develop an E. coli expression system for their enzyme expression. Combined with fermentation and processing protocol, we achieved a ten-fold increase in efficiency within a year.
Today we’re thrilled to announce the formation of our new Biopharma Advisory Board! This council of experts from across the biopharmaceutical industry will provide critical insight into the development of Ginkgo’s core platform service offerings across target discovery, drug discovery, optimization, and manufacturing. The group, which will conduct regular meetings at Ginkgo and with its […]
Overview Enabling RNA therapeutics in linear, circular, or oligo formats RNA therapeutics are programmable medicines. The efficacy, safety, and stability of an RNA drug is determined primarily by its sequence. Ginkgo’s foundry enables our partners to explore large genetic design spaces using both model-guided and unbiased methods. With the power of automation and foundry-scale datasets, […]